Evidence map›Paper›PMID 31881020›Full record

ArticlePloS one2019

Multiscale, multimodal analysis of tumor heterogeneity in IDH1 mutant vs wild-type diffuse gliomas.

Michael E Berens, Anup Sood, Jill S Barnholtz-Sloan, John F Graf, Sanghee Cho, Seungchan Kim, Jeffrey Kiefer, Sara A Byron, Rebecca F Halperin, Sara Nasser and 18 more

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.

0numbers the graph read from it
0cells of the map it votes in
20citing papers in PubMed
2.9field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

20 citing papers in PubMed, 40 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. RapidBiology methods & protocols · 2024
    Article
  10. Article
  11. Preclinical and Clinical Use of Indigenously DevelopedACS pharmacology & translational science · 2023
    Review
  12. Article
  13. Topological-Preserving Membrane Skeleton Segmentation in Multiplex Immunofluorescence Imaging.Proceedings of SPIE--the International Society for Optical Engineering · 2023
    Article
  14. Article
  15. MxIF Q-score: Biology-Informed Quality Assurance for Multiplexed Immunofluorescence Imaging.Medical optical imaging and virtual microscopy image analysis : first International Workshop, MOVI 2022, held in conjunction with MICCAI 2022, Singapore, September 18, 2022, Proceedings. MOVI (Workshop) (1st : 2022 : Singapore) · 2022
    Article
  16. Review
  17. Observational
  18. Article
  19. In Situ Classification of Cell Types in Human Kidney Tissue Using 3D Nuclear Staining.Cytometry. Part A : the journal of the International Society for Analytical Cytology · 2021
    Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

28 authors at 6 institutions in 1 country.

Michael E BerensTranslational Genomics Research Institute, Phoenix, AZ, United States of America.
Anup SoodGE Research Center, Niskayuna, NY, United States of America.
Jill S Barnholtz-SloanDepartment of Population and Quantitative Health Sciences and Case Comprehensive Cancer Center, Case Western Reserve University School of Medicine, Cleveland, OH, United States of America.
John F GrafGE Research Center, Niskayuna, NY, United States of America.ORCID 0000-0002-0396-9867
Sanghee ChoGE Research Center, Niskayuna, NY, United States of America.
Seungchan KimDepartment of Electrical and Computer Engineering, Roy G. Perry College of Engineering, Prairie View A&M University, Prairie View, TX, United States of America.
Jeffrey KieferTranslational Genomics Research Institute, Phoenix, AZ, United States of America.
Sara A ByronTranslational Genomics Research Institute, Phoenix, AZ, United States of America.
Rebecca F HalperinTranslational Genomics Research Institute, Phoenix, AZ, United States of America.
Sara NasserTranslational Genomics Research Institute, Phoenix, AZ, United States of America.
Jonathan AdkinsTranslational Genomics Research Institute, Phoenix, AZ, United States of America.
Lori CuyuganTranslational Genomics Research Institute, Phoenix, AZ, United States of America.
Karen DevineDepartment of Population and Quantitative Health Sciences and Case Comprehensive Cancer Center, Case Western Reserve University School of Medicine, Cleveland, OH, United States of America.
Quinn OstromDepartment of Population and Quantitative Health Sciences and Case Comprehensive Cancer Center, Case Western Reserve University School of Medicine, Cleveland, OH, United States of America.
Marta CouceDepartment of Population and Quantitative Health Sciences and Case Comprehensive Cancer Center, Case Western Reserve University School of Medicine, Cleveland, OH, United States of America.
Leo WolanskyDepartment of Population and Quantitative Health Sciences and Case Comprehensive Cancer Center, Case Western Reserve University School of Medicine, Cleveland, OH, United States of America.
Elizabeth McDonoughGE Research Center, Niskayuna, NY, United States of America.
Shannon SchybergGE Research Center, Niskayuna, NY, United States of America.
Sean DinnGE Research Center, Niskayuna, NY, United States of America.
Andrew E SloanDepartment of Neurosurgery, University Hospitals-Seidman Cancer Center, Cleveland, OH, United States of America.
Michael PradosDepartment of Neurological Surgery, Helen Diller Cancer Center, University of California San Francisco, San Francisco, CA, United States of America.
Joanna J PhillipsDepartment of Neurological Surgery, Helen Diller Cancer Center, University of California San Francisco, San Francisco, CA, United States of America.
Sarah J NelsonDepartment of Radiology and Biomedical Imaging, University of California, San Francisco, CA, United States of America.
Winnie S LiangTranslational Genomics Research Institute, Phoenix, AZ, United States of America.
Yousef Al-KofahiGE Research Center, Niskayuna, NY, United States of America.
Mirabela RusuGE Research Center, Niskayuna, NY, United States of America.
Maria I ZavodszkyGE Research Center, Niskayuna, NY, United States of America.
Fiona GintyGE Research Center, Niskayuna, NY, United States of America.
GE Global Research (United States) · USTranslational Genomics Research Institute · USCase Western Reserve University · USUniversity of California, San Francisco · USPrairie View A&M University · USUniversity Hospitals Seidman Cancer Center · US

Funding

TUMOR METABOLISM PROGRAMP30CA043703 · NCI · CASE WESTERN RESERVE UNIVERSITY · PI Amar Desai · 1987 to 2026
$142.3M
A Novel Molecular Imaging Agent for Surgical Resection of Invasive Brain TumorsR01CA217956 · NCI · CASE WESTERN RESERVE UNIVERSITY · PI BRADY-KALNAY, SUSANN M, GASTINEAU, EDWARD · 2017 to 2021
$3.4M
Chemoprotection & Immune Remodeling after Hematopoietic Progenitor Cell Gene Therapy for GlioblastomaU01CA236215 · NCI · CASE WESTERN RESERVE UNIVERSITY · PI GERSON, STANTON L. · 2019 to 2022
$1.7M
NCI NIH HHS P30 CA043703NCI NIH HHS R01 CA217956NCI NIH HHS U01 CA236215
6 · The paper itself

Abstract

Glioma is recognized to be a highly heterogeneous CNS malignancy, whose diverse cellular composition and cellular interactions have not been well characterized. To gain new clinical- and biological-insights into the genetically-bifurcated IDH1 mutant (mt) vs wildtype (wt) forms of glioma, we integrated data from protein, genomic and MR imaging from 20 treatment-naïve glioma cases and 16 recurrent GBM cases. Multiplexed immunofluorescence (MxIF) was used to generate single cell data for 43 protein markers representing all cancer hallmarks, Genomic sequencing (exome and RNA (normal and tumor) and magnetic resonance imaging (MRI) quantitative features (protocols were T1-post, FLAIR and ADC) from whole tumor, peritumoral edema and enhancing core vs equivalent normal region were also collected from patients. Based on MxIF analysis, 85,767 cells (glioma cases) and 56,304 cells (GBM cases) were used to generate cell-level data for 24 biomarkers. K-means clustering was used to generate 7 distinct groups of cells with divergent biomarker profiles and deconvolution was used to assign RNA data into three classes. Spatial and molecular heterogeneity metrics were generated for the cell data. All features were compared between IDH mt and IDHwt patients and were finally combined to provide a holistic/integrated comparison. Protein expression by hallmark was generally lower in the IDHmt vs wt patients. Molecular and spatial heterogeneity scores for angiogenesis and cell invasion also differed between IDHmt and wt gliomas irrespective of prior treatment and tumor grade; these differences also persisted in the MR imaging features of peritumoral edema and contrast enhancement volumes. A coherent picture of enhanced angiogenesis in IDHwt tumors was derived from multiple platforms (genomic, proteomic and imaging) and scales from individual proteins to cell clusters and heterogeneity, as well as bulk tumor RNA and imaging features. Longer overall survival for IDH1mt glioma patients may reflect mutation-driven alterations in cellular, molecular, and spatial heterogeneity which manifest in discernable radiological manifestations.

Indexed as

AdultAgedBiomarkers, TumorBrain NeoplasmsCase-Control StudiesExome SequencingFemaleFluorescent Antibody TechniqueGenetic HeterogeneityGliomaHumansIsocitrate DehydrogenaseMagnetic Resonance ImagingMaleMiddle AgedMutationBiomarkers, TumorIDH1 protein, humanIsocitrate Dehydrogenase

Identifiers

PMID31881020
PMCPMC6934292
OpenAlexW2996762376

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.